2026 Future Health Industry Conference
Conference Background:
On June 28, 2026, the 2026 Future Health Industry Conference and Synthetic Biology Innovation Industry Summit with the theme "Symbiotic Synthesis, Mutual Benefit Transformation" was successfully held in Shanghai. The conference was guided by the Shanghai Science and Technology Commission and organized by the Shanghai Synthetic Biology Innovation Center. Academicians, experts, government leaders, leading industry companies, investment institutions, and various industrial innovation entities gathered together to explore cutting-edge technology trends, address challenges in industrial transformation, and build a healthy industrial ecosystem. The goal is to establish a coordinated development pathway integrating "government, industry, academia, research, medicine, application, finance, and services" and continue to support the large-scale and high-quality development of China’s synthetic biology industry.
"Synthetic Biology Innovation Transformation Ecosystem Partner" Established:
Frost & Sullivan China Senior Partner and Managing Director Yang XiaochengInvited to the main forum of the conference, Yang Xiaocheng joined the "Synthetic Biology Innovation Transformation Ecosystem Partner" as a third-party professional service provider. The ecosystem partner network operates on the core principles of "joint technical research, platform sharing, market expansion, and capital investment," bringing together various forces from "government, industry, academia, research, medicine, application, finance, and services" to create a collaborative innovation platform focused on the entire chain of synthetic biology transformation.
Frost & Sullivan’s Deep Research Expertise in Synthetic Biology:
This summit featured numerous experts and a strong academic atmosphere. Academician Zhao Guoping, Academician Liu Zhongmin,Academician Liu Dehuaand other industry academics and leading company representatives delivered keynote speeches. Following this, Yang Xiaocheng, Senior Partner and Managing Director of Frost & Sullivan China, gave a speech based on the "Shanghai Synthetic Biology and Biomanufacturing Industry Development White Paper (2025)" released last year. From a global perspective, he analyzed the current state of the synthetic biology industry, emerging technology trends, and future market opportunities, sharing professional insights on industry implementation, commercialization upgrades, and global expansion.
Yang Xiaocheng, Senior Partner and Managing Director of Frost & Sullivan China
In his speech at the summit, Yang Xiaocheng pointed out that synthetic biology, as a cutting-edge research paradigm, focuses on the fundamental design and reconstruction of living systems, representing a key breakthrough in the R&D stage. Biomanufacturing emphasizes the large-scale and stable production of technologies, serving as a crucial foundation for the "from 1 to 100" scale-up of the industry. These two fields work synergistically and mutually enhance each other. Currently, synthetic biology is rapidly penetrating core areas of the national economy, covering six key application scenarios: biomedicine, advanced materials, consumer goods, energy, environmental protection, and agriculture. It provides sustainable industrial solutions and strategic support for addressing major challenges such as resource scarcity, environmental governance, and public health worldwide.
Under the context of the rapid development of new productive forces, Yang Xiaocheng emphasized that vigorously developing synthetic biology and biomanufacturing industries is not only a strategic opportunity for China to seize global industry leadership but also a key path to promoting technological innovation, achieving high-level scientific self-reliance, and fostering new productive forces. He analyzed the current state and trends of the global and Chinese synthetic biology and biomanufacturing industries from four dimensions:
-
The industry policy and regulatory system continues to improve, and institutional support is being accelerated;
-
Global competition and cooperation are intensifying, making the need for autonomous and controllable supply chains more urgent;
-
Capital market investment becomes more rational and cautious, while product innovation and selection requirements increase;
-
The regional clustering effect of the industry remains prominent, and the industrial ecosystem and supporting systems become increasingly complete.
Additionally, Yang Xiaocheng conducted a deep comparative analysis of the global synthetic biology industry development pattern. Synthetic biology has become a strategic high point for countries around the world to invest in. The United States, with long-term national strategic investments, a well-developed innovation ecosystem, and a highly market-oriented capital operation mechanism, remains at the forefront of the global synthetic biology and biomanufacturing industry. The UK, as one of the core sources of synthetic biology research and industrialization, has a strong research foundation, stable funding, and systematic policy support. With the adjustment of regulations after Brexit, it has developed a unique industry development path.
Based on a deep analysis of the industry development paths in European and American benchmark regions, Yang Xiaocheng summarized four key insights that provide important references for the strategic layout and high-quality development of China’s synthetic biology industry.
-
When choosing an industrialization path, we must pay great attention to the top-level design of the business model and carefully plan high-value sectors. We should actively guide innovation entities to focus on high-value areas such as medical health, green materials, and high-end components, avoiding low-end scale competition in cutting-edge technologies, so as to truly leverage the technical premium and disruptive potential of synthetic biology.
-
The construction of regulatory frameworks should emphasize stability and predictability. Clear rules are more important than rapid approvals. We need to establish a classified, scientific, transparent, efficient, and internationally compatible regulatory system to provide clear access paths and development expectations for new products and technologies, thereby stabilizing market confidence, reducing compliance costs, and effectively stimulating innovation vitality over the long term.
-
We must accurately identify and overcome the core bottlenecks from the laboratory to the factory. In particular, pilot scale up and process validation have become common obstacles to the transformation of many excellent results. By learning from international experience, through the establishment of open and shared pilot platforms, demonstration lines, and industrial collaboration networks, we can provide key infrastructure support for innovation enterprises, systematically overcoming the "last mile" of industrialization.
-
The development of synthetic biology essentially depends on an open, collaborative, and talent-driven innovation ecosystem. We need to build a full-chain collaboration mechanism spanning "basic research, technology development, industrial transformation, and market application," strengthen deep integration of industry, academia, and research, and protect intellectual property rights. At the same time, we should attract and cultivate top talents with multi-disciplinary backgrounds in biology, engineering, and data to form a sustainable innovation cycle.
In summary, the future development of China’s synthetic biology industry cannot be limited to mere technological catching-up. It requires systematic and comprehensive planning from multiple dimensions such as strategic choices, regulatory science, industrial foundation, and ecosystem construction. By comprehensively addressing the shortcomings of industrial development and optimizing the industrial development pattern, we can help China build core advantages in the new round of global bio-economy competition and develop a distinctive development path that suits China’s industrial foundation, combines innovation vitality, and is sustainable.
Frost & Sullivan has long been involved in global cutting-edge technology fields and continuously conducts frequent and systematic in-depth industry research, accumulating rich insights into cutting-edge technology and related industry research experience.In August this year, the "Global Synthetic Biology Industry Development Blue Book (2026)" will be launched globally.This white paper relies on in-depth research and collaborative efforts from "government, industry, academia, research, medicine, application, finance, and services" to systematically review the current state of industry development, core challenges, and future trends. It aims to provide professional, forward-looking, and structured authoritative references for government decision-making, institutional investment, industrial layout, and industry development.
Therefore, Frost & Sullivan sincerely invites high-quality enterprises, benchmark parks, and industrial platforms from the upstream and downstream of the industry to participate deeply. Through a first-person perspective, they will share how to face existing challenges and capitalize on business opportunities, demonstrating their core competitiveness in business models, technology platforms, advanced processes, and ecological cooperation. These empirical cases will provide authoritative voices and focused dissemination opportunities for cooperative enterprises globally, while also offering references for investors, research institutions, and the industry, attracting upstream and downstream partners to join the enterprise ecosystem. Participating in this white paper project will help cooperative enterprises enhance their brand presence in the global market and support global brand building and product layout.
To participate in the cooperation, please long-press and scan the QR code below. We will contact you.
